• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Anthrax - Pipeline Review, H2 2012 Product Image

Anthrax - Pipeline Review, H2 2012

  • ID: 2335292
  • November 2012
  • 114 pages
  • Global Markets Direct

Anthrax – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Anthrax - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anthrax.
- A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Anthrax Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Anthrax 8
Anthrax Therapeutics under Development by Companies 10
Anthrax Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Anthrax Therapeutics – Products under Development by Companies 18
Anthrax Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Anthrax Therapeutics Development 20
Aradigm Corporation 20
AlphaRx, Inc. 21
GlaxoSmithKline plc 22
Bavarian Nordic A/S 23
Emergent BioSolutions Inc. 24
Cangene Corporation 25
Oragenics, Inc. 26
PharmAthene, Inc. 27
Soligenix, Inc. 28
Elusys Therapeutics, Inc. 29
Green Cross Corporation 30
Panacea Biotec Limited 31
PolyMedix, Inc. 32
Evolva SA 33
Vaxin, Inc. 34
Phage Biotechnology Corporation 35
Exponential Biotherapies, Inc. 36
NanoBio Corporation 37
ImmunoVaccine Technologies Inc. 38
iBio, Inc. 39
Tetraphase Pharmaceuticals Inc. 40
NasVax Ltd. 41
Pfenex Inc. 42
SelectX Pharmaceuticals, Inc. 43
VectorLogics, Inc. 44
Anthrax – Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 51
raxibacumab - Drug Profile 51
Valortim - Drug Profile 53
ciprofloxacin - Drug Profile 54
ciprofloxacin - Drug Profile 55
MVA-BN Anthrax - Drug Profile 56
Anthrivig - Drug Profile 57
Thravixa - Drug Profile 58
MU-1140 - Drug Profile 59
EV-021 - Drug Profile 60
Drug For Anthrax - Drug Profile 61
oritavancin disphosphate - Drug Profile 62
ETI-204 - Drug Profile 64
PMX-30016 - Drug Profile 65
Anthrax Vaccine - Drug Profile 66
NP-015 - Drug Profile 67
AV-7909 - Drug Profile 68
AdVAV Anthrax Vaccine - Drug Profile 69
Epicutaneous Anthrax Vaccines - Drug Profile 71
VeloThrax - Drug Profile 72
GC-1109 - Drug Profile 73
SMT-15000 - Drug Profile 74
Anthrax Vaccine - Drug Profile 75
Anthrax Monoclonal Antibody - Drug Profile 76
Anthrax Vaccine - Drug Profile 77
PreviThrax - Drug Profile 78
Anthrax Vaccine - Drug Profile 80
TP-271 - Drug Profile 81
VLI-04A - Drug Profile 82
Recombinant Anthrax Vaccine - Drug Profile 83
doxycycline - Drug Profile 84
Anthrax Capsule Vaccine - Drug Profile 85
Snare Antibacterial For Anthrax - Drug Profile 86
Vaccine Adjuvant - Drug Profile 87
Anthrax Vaccine - Drug Profile 88
MU1140-S - Drug Profile 89
Metalloproteinase Inhibitors - Drug Profile 91
Anthrax Therapeutics – Drug Profile Updates 92
Anthrax Therapeutics – Discontinued Products 101
Anthrax Therapeutics - Dormant Products 102
Anthrax – Product Development Milestones 103
Featured News & Press Releases 103
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 111
Disclaimer 111

List of Tables
Number of Products Under Development for Anthrax, H2 2012 11
Products under Development for Anthrax – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Aradigm Corporation, H2 2012 23
AlphaRx, Inc., H2 2012 24
GlaxoSmithKline plc, H2 2012 25
Bavarian Nordic A/S, H2 2012 26
Emergent BioSolutions Inc., H2 2012 27
Cangene Corporation, H2 2012 28
Oragenics, Inc., H2 2012 29
PharmAthene, Inc., H2 2012 30
Soligenix, Inc., H2 2012 31
Elusys Therapeutics, Inc., H2 2012 32
Green Cross Corporation, H2 2012 33
Panacea Biotec Limited, H2 2012 34
PolyMedix, Inc., H2 2012 35
Evolva SA, H2 2012 36
Vaxin, Inc., H2 2012 37
Phage Biotechnology Corporation, H2 2012 38
Exponential Biotherapies, Inc., H2 2012 39
NanoBio Corporation, H2 2012 40
ImmunoVaccine Technologies Inc., H2 2012 41
iBio, Inc., H2 2012 42
Tetraphase Pharmaceuticals Inc., H2 2012 43
NasVax Ltd., H2 2012 44
Pfenex Inc., H2 2012 45
SelectX Pharmaceuticals, Inc., H2 2012 46
VectorLogics, Inc., H2 2012 47
Assessment by Monotherapy Products, H2 2012 48
Assessment by Stage and Route of Administration, H2 2012 50
Assessment by Stage and Molecule Type, H2 2012 53
Anthrax Therapeutics – Drug Profile Updates 95
Anthrax Therapeutics – Discontinued Products 104
Anthrax Therapeutics – Dormant Products 105

List of Figures
Number of Products under Development for Anthrax, H2 2012 11
Products under Development for Anthrax – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 48
Assessment by Route of Administration, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 50
Assessment by Molecule Type, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 52

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos